ArticleBlood advances2025
Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia.
Olayinka Okeleji et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it